Netherton syndrome: New advances in the clinic, disease mechanism and treatment

Expert Review of Dermatology

Volumn 7, Issue 1, 2012, Pages 81-92

  Hovnanian, Alain ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Allergy; Anti TNF ; Elastase 2; Immunoglobulins; KLK5; KLK7; LEKTI; Netherton syndrome; PAR2; Skin barrier; SPINK5; TSLP

Indexed keywords

ANTIHISTAMINIC AGENT; CADHERIN; CALCINEURIN INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; KALLIKREIN 5; LIPID; PIMECROLIMUS; PROFILAGGRIN; PROTEINASE ACTIVATED RECEPTOR 2; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STEROID; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TACROLIMUS; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE PANCREATITIS; ATOPIC DERMATITIS; ATOPY; BRONCHOPNEUMONIA; CLINICAL FEATURE; CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE; GENE EXPRESSION REGULATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOPATHOLOGY; KIDNEY VEIN THROMBOSIS; LEKTI GENE; LOSS OF FUNCTION MUTATION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NETHERTON DISEASE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERSISTENT PULMONARY HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RICKETS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN PRURITUS; SPINK5 GENE; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; TH2 CELL; TREATMENT DURATION; TRICHORRHEXIS;

EID: 84856503544     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.11.85     Document Type: Review

References (100)

1. Comel M. Ichthyosis linearis circumflexa. Dermatologica 98, 133-136 (1949).
2. Netherton EW. A unique case of trichorrhexis nodosa: bamboo hairs. AMA Arch. Derm. 78, 483-487 (1958).
3. Ong C, Harper J. Netherton's syndrome. In: Textbook of Pediatric Dermatology. Harper, J, Orange, A, Prose, N (Eds).Blackwell, Turin, Italy, 1359-1366 (2006).
4. Traupe H. The Comel-Netherton syndrome. In: The Ichthyoses. A Guide To Clinical Diagnosis, Genetic Counseling and Therapy. Traupe H (Ed.). Springer-Verlag, Berlin, Germany, 168-178 (1989).
5. Pruszkowski A, Bodemer C, Fraitag S, Teillac-Hamel D, Amoric JC, de Prost Y. Neonatal and infantile erythrodermas: a retrospective study of 51 patients. Arch. Dermatol. 136(7), 875-880 (2000). (Pubitemid 30604286)
6. Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25(2), 141-142 (2000). (Pubitemid 30394980)
7. Magert HJ, Standker L, Kreutzmann P et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J. Biol. Chem. 274(31), 21499-21502 (1999).
8. Descargues P, Deraison C, Bonnart C et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 37(1), 56-65 (2005). (Pubitemid 40070940)
9. Hewett DR, Simons AL, Mangan NE et al. Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Hum. Mol. Genet. 14(2), 335-346 (2005).
10. Yang T, Liang D, Koch PJ, Hohl D, Kheradmand F, Overbeek PA. Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in Spink5-/- mice. Genes Dev. 18(19), 2354-2358 (2004). (Pubitemid 39304682)
11. Briot A, Deraison C, Lacroix M et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 206(5), 1135-1147 (2009).
12. Sales KU, Masedunskas A, Bey AL et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat. Genet. 42(8), 676-683 (2010).
13. Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J. Invest. Dermatol. 130(12), 2736-2742 (2010).
14. Ny A, Egelrud T. Epidermal hyperproliferation and decreased skin barrier function in mice overexpressing stratum corneum chymotryptic enzyme. Acta Derm. Venereol. 84(1), 18-22 (2004). (Pubitemid 38168357)
15. Hansson L, Backman A, Ny A et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 118(3), 444-449 (2002). (Pubitemid 34227161)
16. Bonnart C, Deraison C, Lacroix M et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest. 120(3), 871-882 (2010).
17. Elias PM, Williams ML, Crumrine D, Schuth M. Inherited disorders of accelerated desquamation. Netherton syndrome. In: Ichthyoses. Clinical, Biochemical, Pathogenic and Diagnostic Assessment. Itin P (Ed.). Karger, Basel, Switzerland, 89-97 (2010).
18. Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr. Dermatol. 13(3), 183-199 (1996). (Pubitemid 26227004)
19. Descargues P, Deraison C, Prost C et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol. 126(7), 1622-1632 (2006).
20. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 11(4), 289-293 (2010).
21. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203(2), 269-273 (2006).
22. Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol. 28(6), 248-251 (2007). (Pubitemid 46810353)
23. Leclerc-Mercier S, Bodemer C, Bourdon- Lanoy E et al. Early skin biopsy is helpful for the diagnosis and management of neonatal and infantile erythrodermas. J. Cutan. Pathol. 37(2), 249-255 (2009).
24. Bitoun E, Micheloni A, Lamant L et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum. Mol. Genet. 12(19), 2417-2430 (2003). (Pubitemid 37220407)
25. Ong C, O'Toole EA, Ghali L et al. LEKTI demonstrable by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome. Br. J. Dermatol. 151(6), 1253-1257 (2004). (Pubitemid 40030174)
26. Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch. Dermatol. 135(7), 823-832 (1999). (Pubitemid 29330807)
27. Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr. Dermatol. 13(3), 183-199 (1996). (Pubitemid 26227004)
28. Powell J. Increasing the likelihood of early diagnosis of Netherton syndrome by simple examination of eyebrow hairs. Arch. Dermatol. 136(3), 423-424 (2000). (Pubitemid 30149125)
29. Neri I, Balestri R, Starace M, Bardazzi F, Patrizi A. Videodermoscopy of eyelashes in Netherton syndrome. J. Eur. Acad. Dermatol. Venereol. 25, 1360-1361 (2011).
30. Rakowska A, Kowalska-Oledzka E, Slowinska M, Rosinska D, Rudnicka L. Hair shaft videodermoscopy in Netherton syndrome. Pediatr. Dermatol. 26(3), 320-322 (2009).
31. de Berker DA, Paige DG, Ferguson DJ, Dawber RP. Golf tee hairs in Netherton disease. Pediatr. Dermatol. 12(1), 7-11 (1995).
32. Goujon E, Beer F, Fraitag S, Hovnanian A, Vabres P. 'Matchstick' eyebrow hairs: a dermoscopic clue to the diagnosis of Netherton syndrome. J. Eur. Acad. Dermatol. Venereol. 24(6), 740-741 (2010).
33. Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int. J. Dermatol. 45(6), 693-697 (2006). (Pubitemid 44056671)
34. Judge MR, Morgan G, Harper JI. A clinical and immunological study of Netherton's syndrome. Br. J. Dermatol. 131(5), 615-621 (1994). (Pubitemid 24344044)
35. Giroux JD, Sizun J, Gardach C, Awad H, Guillois B, Alix D. [Severe hypernatremic dehydration disclosing Netherton syndrome in the neonatal period]. Arch. Fr. Pediatr. 50(7), 585-588 (1993). (Pubitemid 23279199)
36. Stoll C, Alembik Y, Tchomakov D et al. Severe hypernatremic dehydration in an infant with Netherton syndrome. Genet. Couns. 12(3), 237-243 (2001). (Pubitemid 32938685)
37. Beljan G, Traupe H, Metze D, Sunderkotter C. [Comel-Netherton syndrome with bacterial superinfection]. Hautarzt 54(12), 1198-1202 (2003).
38. Arslanagic N, Arslanagic R. [Netherton syndrome with recurrent herpes of facial skin]. Med. Arh. 56(4), 221-224 (2002).
39. Chao SC, Richard G, Lee JY. Netherton syndrome: report of two Taiwanese siblings with staphylococcal scaled skin syndrome and mutation of SPINK5. Br. J. Dermatol. 152(1), 159-165 (2005).
40. Garty BZ, Nimri R. Hypothyroidism in Netherton syndrome. Pediatr. Dermatol. 25(1), 134-135 (2008). (Pubitemid 351315478)
41. Soreide K, Soiland H, Korner H, Haga H, Soreide JA. Acute pancreatitis in a young girl with the Netherton syndrome. J. Pediatr. Surg. 40(11), e69-e72 (2005). (Pubitemid 41625773)
42. Pohl M, Zimmerhackl LB, Hausser I et al. Acute bilateral renal vein thrombosis complicating Netherton syndrome. Eur. J. Pediatr. 157(2), 157-160 (1998). (Pubitemid 28099699)
43. Andre E, Till M, Descargues P et al. [Netherton syndrome: a type of infantile erythroderma with failure to thrive, immune deficiency, rickets. Report of 3 cases]. Arch Pediatr. 12(9), 1364-1367 (2005). (Pubitemid 41206540)
44. Macknet CA, Morkos A, Job L et al. An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation. Pediatr. Dermatol. 25(3), 368-372 (2008). (Pubitemid 351813964)
45. Weber F, Fuchs PG, Pfister HJ, Hinter H, Fritsch P, Hoepfl R. Human papillomavirus infection in Nehterton's syndrome. Br. J. Dermatol. 144, 1044-1049 (2001). (Pubitemid 34203359)
46. Folster-Holst R, Swensson O, Stockfleth E, Monig H, Mrowietz U, Christophers E. Comel-Netherton syndrome complicated by papillomatous skin lesions containing human papillomaviruses 51 and 52 and plane warts containing human papillomavirus 16. Br. J. Dermatol. 140(6), 1139-1143 (1999). (Pubitemid 29284591)
47. Li AL, Walsh S, McKay DR. Surgical management of a giant condyloma of Buschke-Lowenstein in a patient with Netherton syndrome using the pedicled anterolateral thigh flap - a case report. J. Plast. Reconstr. Aesthet. Surg. 64, 1533-1536 (2011).
48. Krasagakis K, Ioannidou DJ, Stephanidou M, Manios A, Panayiotides JG, Tosca AD. Early development of multiple epithelial neoplasms in Netherton syndrome. Dermatology 207(2), 182-184 (2003). (Pubitemid 37034349)
49. Saghari S, Woolery-Lloyd H, Nouri K. Squamous cell carcinoma in a patient with Netherton's syndrome. Int. J. Dermatol. 41(7), 415-416 (2002).
50. Hintner H, Jaschke E, Fritsch P. [Netherton syndrome: weakened immunity, generalized verrucosis and carcinogenesis]. Hautarzt 31(8), 428-432 (1980). (Pubitemid 11246149)
51. Kubler HC, Kuhn W, Rummel HH, Kaufmann I, Kaufmann M. [Development of cancer (vulvar cancer) in the Netherton syndrome (ichthyosis, hair anomalies, atopic diathesis)]. Geburtshilfe Frauenheilkd. 47(10), 742-744 (1987).
52. Van Gysel D, Koning H, Baert MR, Savelkoul HF, Neijens HJ, Oranje AP. Clinico-immunological heterogeneity in Comel-Netherton syndrome. Dermatology 202(2), 99-107 (2001).
53. Renner ED, Hartl D, Rylaarsdam S et al. Comel-Netherton syndrome defined as primary immunodeficiency. J. Allergy Clin. Immunol. 124(3), 536-543 (2009).
54. Stryk S, Siegfried EC, Knutsen AP. Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Pediatr. Dermatol. 16(1), 19-22 (1999). (Pubitemid 29102626)
55. Sprecher E, Chavanas S, DiGiovanna JJ et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J. Invest. Dermatol. 117(2), 179-187 (2001). (Pubitemid 34205699)
56. Sprecher E, Tesfaye-Kedjela A, Ratajczak P, Bergman R, Richard G. Deleterious mutations in SPINK5 in a patient with congenital ichthyosiform erythroderma: molecular testing as a helpful diagnostic tool for Netherton syndrome. Clin. Exp. Dermatol. 29(5), 513-517 (2004). (Pubitemid 39278199)
57. Bitoun E, Bodemer C, Amiel J et al. Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis. Prenat. Diagn. 22(2), 121-126 (2002). (Pubitemid 34193187)
58. Bitoun E, Chavanas S, Irvine AD et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J. Invest. Dermatol. 118(2), 352-361 (2002). (Pubitemid 34158493)
59. Raghunath M, Tontsidou L, Oji V et al. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J. Invest. Dermatol. 123(3), 474-483 (2004). (Pubitemid 39095617)
60. Mizuno Y, Suga Y, Muramatsu S, Hasegawa T, Shimizu T, Ogawa H. A Japanese infant with localized ichthyosis linearis circumflexa on the palms and soles harbouring a compound heterozygous mutation in the SPINK5 gene. Br. J. Dermatol. 153(3), 661-663 (2005). (Pubitemid 41248232)
61. Mizuno Y, Suga Y, Haruna K et al. A case of a Japanese neonate with congenital ichthyosiform erythroderma diagnosed as Netherton syndrome. Clin. Exp. Dermatol. 31(5), 677-680 (2006). (Pubitemid 44086799)
62. Shimomura Y, Sato N, Kariya N, Takatsuka S, Ito M. Netherton syndrome in two Japanese siblings with a novel mutation in the SPINK5 gene: immunohistochemical studies of LEKTI and other epidermal molecules. Br. J. Dermatol. 153(5), 1026-1030 (2005). (Pubitemid 41540774)
63. Lin SP, Huang SY, Tu ME et al. Netherton syndrome: mutation analysis of two Taiwanese families. Arch. Dermatol. Res. 299(3), 145-150 (2007).
64. Lacroix M, Lacaze-Buzy L, Furio L et al. Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations. J. Invest. Dermatol. doi:10.1038/ jid.2011.366 (2011) (Epub ahead of print).
65. Chao SC, Tsai YM, Lee JY. A compound heterozygous mutation of the SPINK5 gene in a Taiwanese boy with Netherton syndrome. J. Formos. Med. Assoc. 102(6), 418-423 (2003). (Pubitemid 37336698)
66. Fong K, Akdeniz S, Isi H, Taskesen M, McGrath JA, Lai-Cheong JE. New homozygous SPINK5 mutation, p. Gln333X, in a Turkish pedigree with Netherton syndrome. Clin. Exp. Dermatol. 36(4), 412-415 (2010).
67. Alpigiani MG, Salvati P, Schiaffino MC et al. A new SPINK5 mutation in a patient with Netherton syndrome: a case report. Pediatr. Dermatol. doi:10.1111/j.1525-1470.2011.01525.x (2011) (Epub ahead of print).
68. Di WL, Hennekam RC, Callard RE, Harper JI. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins. Br. J. Dermatol. 161(2), 404-412 (2009).
69. Mallory SB, Krafchik BR. What syndrome is this? Ped. Dermatol. 9, 157-160 (1992).
70. De Felipe I, Vazquez-Doval FJ, Vicente J. Comel-Netherton syndrome. A diagnostic challenge. Br. J. Dermatol. 137(3), 468-469 (1997).
71. Krol A, Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol. Ther. 19(2), 73-82 (2006).
72. Shwayder T, Banerjee S. Netherton syndrome presenting as congenital psoriasis. Pediatr. Dermatol. 14(6), 473-476 (1997). (Pubitemid 28012031)
73. Sardy M, Fay A, Karpati S, Horvath A. Comel-Netherton syndrome and peeling skin syndrome type B: overlapping syndromes or one entity? Int. J. Dermatol. 41(5), 264-268 (2002). (Pubitemid 34773448)
74. Hachem JP, Wagberg F, Schmuth M et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol. 126(7), 1609-1621 (2006).
75. Komatsu N, Saijoh K, Jayakumar A et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J. Invest. Dermatol. 128(5), 1148-1159 (2008). (Pubitemid 351543199)
76. Fontao L, Laffitte E, Briot A et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J. Invest. Dermatol. 131, 1947-1950 (2011).
77. Allen A, Siegfried E, Silverman R et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 137(6), 747-750 (2001). (Pubitemid 32577856)
78. Shah KN, Yan AC. Low but detectable serum levels of tacrolimus seen with the use of very dilute, extemporaneously compounded formulations of tacrolimus ointment in the treatment of patients with netherton syndrome. Arch. Dermatol. 142(10), 1362-1363 (2006). (Pubitemid 44583294)
79. Saif GB, Al-Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int. J. Dermatol. 46(3), 290-294 (2007). (Pubitemid 46390289)
80. Oji V, Beljan G, Beier K, Traupe H, Luger TA. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br. J. Dermatol. 153(5), 1067-1068 (2005). (Pubitemid 41540783)
81. Henno A, Choffray A, De La Brassinne M. [Improvement of Netherton syndrome associated erythroderma in two adult sisters through use of topical pimecrolimus]. Ann. Dermatol. Venereol. 133(1), 71-72 (2006). (Pubitemid 43195963)
82. Yan AC, Honig PJ, Ming ME, Weber J, Shah KN. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch. Dermatol. 146(1), 57-62 (2010).
83. Halverstam CP, Vachharajani A, Mallory SB. Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. Pediatr. Dermatol. 24(1), 42-45 (2007).
84. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365(14), 1315-1327 (2011).
85. Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat. Rev. Immunol. 4(12), 978-988 (2004). (Pubitemid 39620072)
86. Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J. Invest. Dermatol. 129(8), 1892-1908 (2009).
87. Walley AJ, Chavanas S, Moffatt MF et al. Gene polymorphism in Netherton and common atopic disease. Nat. Genet. 29(2), 175-178 (2001). (Pubitemid 32952654)
88. Zhao LP, Di Z, Zhang L et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in Northeast China. J. Eur. Acad. Dermatol. Venereol. doi:10.1111/j.1468-3083.2011.04120.x (2011) (Epub ahead of print).
89. Kato A, Fukai K, Oiso N, Hosomi N, Murakami T, Ishii M. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br. J. Dermatol. 148(4), 665-669 (2003). (Pubitemid 36629743)
90. Liu Q, Xia Y, Zhang W et al. A functional polymorphism in the SPINK5 gene is associated with asthma in a Chinese Han population. BMC Med. Genet. 10, 59 (2009).
91. Namkung JH, Lee JE, Kim E et al. Hint for association of single nucleotide polymorphisms and haplotype in SPINK5 gene with atopic dermatitis in Koreans. Exp. Dermatol. 19(12), 1048-1053 (2010).
92. Nishio Y, Noguchi E, Shibasaki M et al. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun. 4(7), 515-517 (2003). (Pubitemid 38967619)
93. Rihs HP, Kowal A, Raulf-Heimsoth M, Degens PO, Landt O, Bruning T. Rapid detection of the SPINK5 polymorphism Glu420Lys by real-time PCR technology. Clin. Chim. Acta 355(1-2), 185-189 (2005).
94. Weidinger S, Baurecht H, Wagenpfeil S et al. Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. J. Allergy Clin. Immunol. 122(3), 560-568 e564 (2008).
95. Kreutzmann P, Schulz A, Standker L, Forssmann WG, Magert HJ. Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1), 75-81 (2004). (Pubitemid 38340640)
96. Di WL, Larcher F, Semenova E et al. Ex vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 19(2), 408-416 (2011).
97. Roedl D, Oji V, Buters JT, Behrendt H, Braun-Falco M. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients. J. Dermatol. Sci. 61(3), 194-198 (2011).
98. Di WL, Semenova E, Larcher F et al. Human involucrin promoter mediates repression resistant and compartment specific LEKTI expression. Hum. Gene Ther. doi:10.1089/hum.2011.091 (2011) (Epub ahead of print).
99. Matsui T, Miyamoto K, Kubo A et al. SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol. Med. 6, 320-333 (2011).
100. The Human Gene Mutation Database. www.hgmd.org